PLK1 and lung carcinoma: Lung cancer cells with wild-type TP53 exist resistance to PLK1 inhibitor GSK461364A via activating a postmitotic tetraploid checkpoint and arrest in a pseudo-G1 state following PLK1 inhibition, while RNA silencing of TP53 increased the antitumor activity of GSK461364A (Degenhardt et al., 2010).